Curevac has been granted a patent for an immunostimulatory composition containing mRNA that encodes multiple prostate cancer antigens. This composition aims to elicit an adaptive immune response and is intended for use in vaccines targeting prostate cancer, including hormone-refractory types. GlobalData’s report on Curevac gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Curevac, Personalized cancer vaccines was a key innovation area identified from patents. Curevac's grant share as of July 2024 was 37%. Grant share is based on the ratio of number of grants to total number of patents.
Mrna vaccine for prostate cancer treatment
The granted patent US12048738B2 outlines a series of claims related to isolated messenger RNA (mRNA) that encodes the Prostate-Specific Antigen (PSA) polypeptide. The primary focus is on mRNA sequences that are at least 90% identical to a specific sequence (SEQ ID NO: 3) and can encode either the full PSA polypeptide or its antigenic fragments. The claims further specify variations in the degree of identity, with some claims requiring 95%, 97%, or even 100% identity to the reference sequence. Additionally, the mRNA may be complexed with cationic compounds, such as lipids or proteins, and can include structural features like a 5' cap, poly-A or poly-C tails, untranslated regions, and nucleotide analogs.
Moreover, the patent includes claims for methods of treating prostate cancer by administering the isolated mRNA and for creating immunostimulatory compositions that combine the PSA-encoding mRNA with other RNA sequences encoding different prostate-related antigens. These compositions aim to stimulate an anti-tumor immune response in subjects. The patent also describes a kit that contains both the PSA-encoding mRNA and additional RNA sequences for other prostate antigens, facilitating a comprehensive approach to immunotherapy for prostate cancer.
To know more about GlobalData’s detailed insights on Curevac, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
